---
document_datetime: 2023-09-21 17:19:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/irbesartan-hydrochlorothiazide-bms-epar-procedural-steps-taken-authorisation_en.pdf
document_name: irbesartan-hydrochlorothiazide-bms-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3358073
conversion_datetime: 2025-12-24 14:40:14.379492
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Bristol-Myers Squibb Pharma EEIG submitted on 6 September 2006 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Irbesartan Hydrochlorothiazide BMS, through the centralised procedure according to Regulation (EC) No 726/2004.

The  legal  basis  for  this  application  refers  to  Article  10c  of  Directive  2001/83/EC,  as  amended  relating to informed consent from the marketing authorisation holder, Bristol-Myers Squibb Pharma EEIG, for the authorised medicinal product KARVEZIDE (EU/1/98/085/001-022).

## Scientific Advice:

<!-- image -->

The applicant did not seek scientific advice at the CHMP. Licensing status: The initial product, KARVEZIDE, has been given a Community Marketing Authorisation on 16 October 1998. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Concepción Prieto Yerro Co-Rapporteur: Pirjo Laitinen-Parkkonen 2. Steps taken for the assessment of the product  The application was received by the EMEA on 6 September 2006.  The procedure started on 27 September 2006  The Rapporteur's first Assessment Report was circulated to all CHMP members on 16 October 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 October 2006.  The  Rapporteur  circulated  an  updated  Assessment  Report  to  all  CHMP  members  on 13 November 2006.  During  the  meeting  on  13-16  November  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Irbesartan Hydrochlorothiazide BMS on 16 November 2006.  The  applicant  provided  the  letter  of  undertaking  on  the  follow-up  measures  to  be fulfilled post-authorisation on 14 November 2006.  The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 19 January 2007. Medicinal product no longer authorised